相关概念视频
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
2.8K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
2.8K
01:26Asthma-II: Pathophysiology and Classification
2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
2.8K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.8K
01:20COPD: Pathogenesis and Clinical Features
271
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
271
01:22Chronic Obstructive Pulmonary Disease
1.2K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.2K
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
2.8K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
2.8K
您也可能阅读
相关文章
通过共同作者、期刊和引用图与本文相关的文章。
排序
Same author
Comparative transcriptomics in human COPD reveals dysregulated genes uniquely expressed in ferrets.
Respiratory research·2022
Same author
Losartan metabolite EXP3179 is a unique blood pressure-lowering AT1R antagonist with direct, rapid endothelium-dependent vasoactive properties.
Vascular pharmacology·2022
Same author
Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis.
The European respiratory journal·2022
相关实验视频
Updated: Jun 30, 2025
13:28
Methodology for Sputum Induction and Laboratory Processing
Published on: December 17, 2017
27.6K
在COPD的2型呼吸道炎症.
Francesca Polverino1, Don D Sin2
1Pulmonary and Critical Care Medicine, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
The European respiratory journal
|March 14, 2024
概括
以前在慢性阻塞性肺病 (COPD) 中被低估的2型炎症现在被认为是大约三分之一的患者的关键驱动因素. 准这种炎症为COPD管理提供了一个有前途的新治疗途径.
科学领域:
- 肺部医学 肺部医学
- 免疫学 免疫学 免疫学
- 呼吸道疾病 呼吸道疾病
背景情况:
- 慢性阻塞性肺病 (COPD) 影响全球近4亿人,导致大量住院治疗和死亡.
- 慢性肺炎的特征是气道炎症,但与喘相比,2型炎症的作用在历史上被认为是轻微的.
研究的目的:
- 确定关键分子和免疫细胞参与COPD的2型呼吸道炎症.
- 审查针对COPD2型炎症的生物药物最近的治疗试验结果.
- 探索未来开发2型免疫调节剂用于COPD治疗的方向.
主要方法:
- 关于COPD2型炎症的最近研究的文献综述.
- 对免疫细胞群和COPD涉及的分子途径的分析.
- 对针对2型途径的生物疗法进行临床试验数据的评估.
主要成果:
- 大约三分之一的COPD患者表现出显著的2型炎症,这表明它是疾病的关键驱动因素.
- 参与COPD相关的2型免疫的免疫细胞和分子可能与严重喘中的免疫细胞和分子不同.
- 最近针对2型途径的生物试验显示出潜在的潜力,尽管具体的疗效有所不同.
结论:
- 2型炎症是COPD患者的一个子集中重要的,但经常被忽视的组成部分.
- 准2型免疫路径代表了COPD的可行的治疗策略.
- 对2型免疫调节剂的进一步研究和开发是有效的COPD管理的必要条件.